CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2025-12-26 11:25Core Viewpoint - Xiangsheng Medical (688358) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 343 million yuan, a year-on-year decrease of 5.27% [2]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year [2]. - The net profit after deducting non-recurring items was 86.97 million yuan, a decrease of 2.69% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 107 million yuan, a decline of 6.68% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 24.22 million yuan, an increase of 41.95% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 23.14 million yuan, an increase of 53.63% year-on-year [2]. - The company's debt ratio stood at 11.24%, with investment income of 3.01 million yuan and financial expenses of -16.53 million yuan [2]. - The gross profit margin was 59.82% [2]. Market Activity - As of December 26, 2025, Xiangsheng Medical's stock closed at 30.1 yuan, down 0.89%, with a turnover rate of 0.81% and a trading volume of 9,047 hands, amounting to a transaction value of 27.26 million yuan [1]. - On December 26, the net inflow of main funds was 2.07 million yuan, accounting for 7.6% of the total transaction value, while retail investors had a net outflow of 2.65 million yuan, representing 9.74% of the total transaction value [1]. Analyst Ratings - In the last 90 days, three institutions have given buy ratings for Xiangsheng Medical [3].